Kane Biotech (TSE:KNE) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Kane Biotech Inc. has reported a significant second quarter in 2024, marked by a $10.4M gain from the sale of STEM and a robust 23% increase in total revenue compared to the previous year. The company has not only settled all interest-bearing debt but also expanded its market reach with new distribution agreements and advancements like the MDSAP Quality Certification and FDA clearance enhancements for their revyve Antimicrobial Wound Gel product.
For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue